FIELD: pharmacology.
SUBSTANCE: group of inventions can be used to treat neoplasm associated with excessive expression or amplification of HER2. The use concerns a combination of an mTOR inhibitor selected from the group consisting of rapamycin (sirolimus), 42-O-(2-hydroxy)ethyl rapamycin (etorolimus), CCI-779 (tamsirolimus), and pharmaceutically acceptable salts thereof; And (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide (HKI-272). The method of treatment comprises administering a combination of the mTOR inhibitor and HKI-272. The product of the invention contains an inhibitor of mTOR and HKI-272.
EFFECT: use of inventions allows to increase the effectiveness of treatment due to the synergistic effect of the combination.
59 cl, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-TUMOUR COMBINATIONS MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2006 |
|
RU2451524C2 |
| ANTICANCER ACTIVITY OF CCI-779 IN PAPILLARY RENAL CELL CARCINOMA | 2008 |
|
RU2501559C2 |
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2009 |
|
RU2492860C2 |
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2013 |
|
RU2670974C2 |
| PROCESS FOR TREATMENT OF BREAST CANCER USING NERATINIB | 2014 |
|
RU2685715C2 |
| ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE | 2009 |
|
RU2498804C2 |
| TREATMENT REGIMEN FOR BREAST CANCER USING NERATINIB | 2019 |
|
RU2804713C2 |
| COMBINATION OF OZOGAMICIN INOTUZUMAB AND TORIZEL FOR TREATING CANCER | 2012 |
|
RU2607594C2 |
| ANTI-TUMOR COMPOSITIONS CONTAINING RAPAMICINE DERIVATIVE AND AROMATASE INHIBITOR | 2004 |
|
RU2355399C2 |
| COMBINED THERAPY WITH AFUCOSYLATED CD20 ANTIBODY AND mTOR INHIBITOR | 2011 |
|
RU2585489C2 |
